VarmX and Rentschler Biopharma expand collaboration from early development to late ‑ stage and commercial manufacturing of VMX-C001 VMX ‑ C001 ...

Hemophilia A and B involve deficiencies in coagulation factors VIII and IX, with traditional treatments requiring frequent infusions. Nonfactor therapies, including Hemlibra and rebalancing agents, ...

A recent study provides new insights into the mechanisms of coagulation in persons with haemophilia A, the most common form of haemophilia. The research team was able to show that saliva contains ...

All that most laymen know about hemophilia is that it is an odd and dangerous disease of the blood that strikes men only, although it is transmitted by women. Medical researchers have learned a great ...

Rentschler Biopharma, a global CDMO for biopharmaceuticals, and VarmX, a biotech company developing direct oral ...

The phase 3 trial of valoctocogene roxaparvovec for severe hemophilia A showed it reduced bleeding events as well as the use of factor VIII concentrates. A phase 3 trial of valoctocogene roxaparvovec, ...

Researchers used a technique in genetic analysis termed Mendelian randomization to examine 12 coagulation measures, uncovering four that are associated with migraine susceptibility. Nearly 15 percent ...

‌Factor VII deficiency is a rare genetic disorder. It occurs when your body can’t produce enough clotting factor VII, which helps in healing wounds. It can be hereditary or be caused by an underlying ...

The severity of factor X deficiency varies from person to person. Your body still produces 40% or more of the normal amount of factor X in mild cases. You may have no symptoms or only very minor ones.

Nearly 15 percent of the U.S. population experiences migraine. One subtype of migraine that is not well understood is migraine with aura (MA). Individuals who experience MA often see flashing lights, ...